{
  "patient_id": "sarah_m",
  "extraction_metadata": {
    "extracted_from": [
      "01_Prior_Auth_Request_Form.pdf",
      "02_Laboratory_Results.pdf",
      "03_PET_CT_Report.pdf",
      "04_Bone_Marrow_Biopsy.pdf",
      "05_Clinical_Summary.pdf"
    ],
    "extraction_date": "2026-02-01",
    "extraction_method": "clinical_document_extraction"
  },

  "demographics": {
    "first_name": "Sarah",
    "last_name": "Mitchell",
    "date_of_birth": "1973-08-14",
    "age": 52,
    "gender": "Female",
    "ethnicity": "Caucasian",
    "address": {
      "street": "1425 Hawthorne Boulevard",
      "city": "Portland",
      "state": "OR",
      "zip": "97201"
    },
    "phone": "503-555-0234",
    "mrn": "SARAH_M",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "insurance": {
    "primary": {
      "payer_name": "BCBS",
      "payer_id": "BCBS_FEP",
      "plan_name": "Blue Cross Blue Shield Federal Employee Program",
      "plan_type": "PPO",
      "member_id": "FEP334829176",
      "group_number": "FEP-STANDARD-2024",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  },

  "prescriber": {
    "name": "Dr. Rachel Nguyen",
    "credentials": "MD, FACP",
    "npi": "1987654321",
    "specialty": "Hematology-Oncology",
    "practice_name": "Oregon Cancer Institute",
    "address": {
      "street": "3181 SW Sam Jackson Park Road",
      "city": "Portland",
      "state": "OR",
      "zip": "97239"
    },
    "phone": "503-555-0400",
    "fax": "503-555-0401",
    "rems_certified_facility": true,
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "medication_request": {
    "medication_name": "Lisocabtagene maraleucel",
    "brand_name": "Breyanzi",
    "j_code": "Q2054",
    "dose": "Single infusion, patient-specific dose",
    "route": "Intravenous infusion",
    "frequency": {
      "regimen": "Single dose — lymphodepleting chemotherapy followed by CAR-T infusion"
    },
    "duration_requested": "One-time infusion authorization",
    "quantity_requested": "1 infusion",
    "site_of_care": "Certified REMS treatment center",
    "start_date_requested": "2026-03-01",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "diagnoses": [
    {
      "rank": "primary",
      "icd10_code": "C83.30",
      "description": "Diffuse large B-cell lymphoma, unspecified site",
      "status": "active",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    },
    {
      "rank": "secondary",
      "icd10_code": "C83.38",
      "description": "Diffuse large B-cell lymphoma, lymph nodes of multiple sites",
      "status": "active",
      "source_document": "03_PET_CT_Report.pdf"
    }
  ],

  "disease_activity": {
    "assessment_date": "2026-01-10",
    "ann_arbor_stage": "IIIB",
    "ecog_performance_status": 1,
    "ecog_interpretation": "Restricted in physically strenuous activity but ambulatory",
    "ipi_score": 3,
    "ipi_risk_category": "High-intermediate",
    "disease_status": "relapsed_refractory",
    "lines_of_therapy_completed": 3,
    "source_documents": ["01_Prior_Auth_Request_Form.pdf", "05_Clinical_Summary.pdf"]
  },

  "clinical_history": {
    "chief_complaint": "Progressive lymphadenopathy with constitutional symptoms after third-line therapy failure",
    "history_of_present_illness": "52-year-old female with relapsed/refractory DLBCL. Originally diagnosed March 2024 with Stage IIIB disease. Received first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) x6 cycles with initial complete response. Relapsed at 8 months. Received second-line R-ICE (rituximab, ifosfamide, carboplatin, etoposide) x3 cycles — partial response but not eligible for autologous stem cell transplant due to insufficient stem cell mobilization. Third-line gemcitabine/oxaliplatin/rituximab x4 cycles with progressive disease on restaging PET/CT. Now referred for CAR-T cell therapy.",
    "prior_car_t_therapy": false,
    "prior_gene_therapy": false,
    "source_document": "05_Clinical_Summary.pdf"
  },

  "prior_treatments": [
    {
      "medication_name": "R-CHOP",
      "drug_class": "Anthracycline-containing chemoimmunotherapy",
      "components": ["Rituximab (anti-CD20)", "Cyclophosphamide", "Doxorubicin (anthracycline)", "Vincristine", "Prednisone"],
      "dose": "Standard dosing per protocol",
      "start_date": "2024-03-15",
      "end_date": "2024-08-20",
      "cycles_completed": 6,
      "outcome": "complete_response_then_relapsed",
      "outcome_description": "Achieved complete metabolic response on end-of-treatment PET/CT (Deauville 2). Relapsed at 8 months with new cervical and retroperitoneal lymphadenopathy.",
      "contains_anti_cd20": true,
      "contains_anthracycline": true,
      "source_document": "05_Clinical_Summary.pdf"
    },
    {
      "medication_name": "R-ICE",
      "drug_class": "Platinum-based salvage chemoimmunotherapy",
      "components": ["Rituximab (anti-CD20)", "Ifosfamide", "Carboplatin", "Etoposide"],
      "dose": "Standard dosing per protocol",
      "start_date": "2025-05-01",
      "end_date": "2025-07-15",
      "cycles_completed": 3,
      "outcome": "partial_response",
      "outcome_description": "Partial metabolic response (Deauville 4). Stem cell mobilization attempted but failed — insufficient CD34+ yield. Not eligible for autologous transplant.",
      "hsct_eligible": false,
      "hsct_reason": "Failed stem cell mobilization",
      "contains_anti_cd20": true,
      "source_document": "05_Clinical_Summary.pdf"
    },
    {
      "medication_name": "GemOx-R",
      "drug_class": "Third-line chemoimmunotherapy",
      "components": ["Gemcitabine", "Oxaliplatin", "Rituximab (anti-CD20)"],
      "start_date": "2025-09-01",
      "end_date": "2025-12-15",
      "cycles_completed": 4,
      "outcome": "progressive_disease",
      "outcome_description": "Progressive disease on restaging PET/CT with new hepatic lesions. Biopsy-confirmed persistent DLBCL.",
      "contains_anti_cd20": true,
      "source_document": "05_Clinical_Summary.pdf"
    }
  ],

  "laboratory_results": {
    "collection_date": "2026-01-08",
    "source_document": "02_Laboratory_Results.pdf",
    "panels": {
      "cbc": {
        "panel_name": "Complete Blood Count",
        "results": [
          {"test": "WBC", "value": 5.8, "unit": "x10^9/L", "reference_range": "4.5-11.0", "flag": null},
          {"test": "Hemoglobin", "value": 11.4, "unit": "g/dL", "reference_range": "12.0-16.0", "flag": "L"},
          {"test": "Platelets", "value": 165, "unit": "x10^9/L", "reference_range": "150-400", "flag": null},
          {"test": "ANC", "value": 3.2, "unit": "x10^9/L", "reference_range": "1.5-8.0", "flag": null},
          {"test": "ALC", "value": 0.9, "unit": "x10^9/L", "reference_range": "1.0-4.8", "flag": "L"}
        ]
      },
      "cmp": {
        "panel_name": "Comprehensive Metabolic Panel",
        "results": [
          {"test": "Creatinine", "value": 0.9, "unit": "mg/dL", "reference_range": "0.6-1.2", "flag": null},
          {"test": "AST", "value": 32, "unit": "U/L", "reference_range": "10-40", "flag": null},
          {"test": "ALT", "value": 28, "unit": "U/L", "reference_range": "7-56", "flag": null},
          {"test": "Total Bilirubin", "value": 0.8, "unit": "mg/dL", "reference_range": "0.1-1.2", "flag": null},
          {"test": "LDH", "value": 285, "unit": "U/L", "reference_range": "140-280", "flag": "H"},
          {"test": "Albumin", "value": 3.4, "unit": "g/dL", "reference_range": "3.5-5.0", "flag": "L"}
        ]
      },
      "viral_screening": {
        "panel_name": "Pre-CAR-T Viral Screening",
        "results": [
          {"test": "HBsAg", "value": "Negative", "flag": null},
          {"test": "Anti-HBc", "value": "Negative", "flag": null},
          {"test": "HCV Antibody", "value": "Negative", "flag": null},
          {"test": "HIV 1/2 Ab/Ag", "value": "Negative", "flag": null}
        ]
      }
    }
  },

  "procedures": {
    "pet_ct": {
      "procedure_name": "PET/CT Restaging",
      "procedure_date": "2026-01-05",
      "indication": "Restaging after third-line therapy",
      "findings": "Progressive disease with new hepatic lesions, persistent cervical and retroperitoneal lymphadenopathy. Maximum SUV 18.2 in largest retroperitoneal node (4.8 cm). Deauville 5.",
      "source_document": "03_PET_CT_Report.pdf"
    },
    "bone_marrow_biopsy": {
      "procedure_name": "Bone Marrow Aspirate and Biopsy",
      "procedure_date": "2026-01-12",
      "findings": "No marrow involvement by lymphoma. Adequate trilineage hematopoiesis. Cellularity 40%.",
      "source_document": "04_Bone_Marrow_Biopsy.pdf"
    }
  },

  "organ_function_assessment": {
    "cardiac": {
      "lvef": "55%",
      "method": "Echocardiogram",
      "date": "2026-01-15",
      "status": "adequate"
    },
    "pulmonary": {
      "status": "adequate",
      "notes": "No significant pulmonary disease"
    },
    "hepatic": {
      "status": "adequate",
      "notes": "AST/ALT within normal limits, bilirubin normal"
    },
    "renal": {
      "status": "adequate",
      "creatinine_clearance": "82 mL/min"
    }
  },

  "pa_criteria_assessment": {
    "diagnosis_confirmed": {
      "met": true,
      "evidence": "Biopsy-confirmed DLBCL (ICD-10 C83.30). CD19-positive on immunohistochemistry."
    },
    "age_requirement": {
      "met": true,
      "evidence": "Patient is 52 years old (>=18)"
    },
    "prior_anti_cd20": {
      "met": true,
      "evidence": "Rituximab included in all 3 prior lines (R-CHOP, R-ICE, GemOx-R)"
    },
    "prior_anthracycline": {
      "met": true,
      "evidence": "Doxorubicin (anthracycline) included in first-line R-CHOP"
    },
    "lines_of_therapy": {
      "met": true,
      "evidence": "3 prior lines of systemic therapy completed"
    },
    "rems_facility": {
      "met": true,
      "evidence": "Oregon Cancer Institute is a certified REMS treatment center"
    },
    "no_cns_lymphoma": {
      "met": true,
      "evidence": "No CNS involvement on staging workup"
    },
    "adequate_organ_function": {
      "met": true,
      "evidence": "LVEF 55%, CrCl 82, liver function normal"
    },
    "no_prior_gene_therapy": {
      "met": true,
      "evidence": "No prior CAR-T or gene therapy"
    },
    "no_active_infection": {
      "met": true,
      "evidence": "Viral screening negative, no active infections"
    }
  },

  "overall_pa_readiness": {
    "status": "READY_FOR_SUBMISSION",
    "blocking_issues": [],
    "criteria_met_count": 10,
    "criteria_total_count": 10,
    "policy_version_impact": {
      "qualifies_under_2024": true,
      "qualifies_under_2025": true,
      "impact_notes": "Patient meets all criteria under both 2024 and 2025 BCBS policy versions. R-CHOP contains both anti-CD20 (rituximab) and anthracycline (doxorubicin), satisfying the new 2025 step therapy requirements."
    }
  }
}
